SCHEMBL1027304

SCHEMBL1027304

COc1ccc2c(c1)CN(N(C)C(=O)CN(CC(=O)O)c1cc(-c3noc(C)n3)ccc1C)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.40
MAPT P10636 4/20 0.40
POLB P06746 1/20 0.38
P2RX3 P56373 2/20 0.38
TNF P01375 1/20 0.36
HTR1D P28221 2/20 0.36
HTR1B P28222 2/20 0.36
HTR2A P28223 2/20 0.36
MAPK14 Q16539 1/20 0.36
DRD3 P35462 1/20 0.35
ATM Q13315 1/20 0.35
HTT P42858 2/20 0.35
NPC1 O15118 1/20 0.35
THRB P10828 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1026588 0.89 MAPK14 (0.39) LMNAMAPTPOLBMAPK14HTT
SCHEMBL11975515 0.88 AHCY (0.49) LMNAMAPTPOLBMAPK14DRD3
SCHEMBL1027694 0.87 HCRTR1 (0.36) LMNAMAPTHTR1DHTR1BHTR2A
SCHEMBL11974613 0.86 AHCY (0.41) LMNAMAPTP2RX3MAPK14DRD3
SCHEMBL1029163 0.84 AHCY (0.39) LMNAMAPTHTR1DHTR1BHTR2A
SCHEMBL1025174 0.84 MAPK14 (0.37) LMNAMAPTPOLBHTR1DHTR1B
SCHEMBL1027906 0.82 MAPK14 (0.35) LMNAMAPTMAPK14THRB
SCHEMBL1028240 0.80 MAPK14 (0.41) LMNAMAPTPOLBP2RX3MAPK14
SCHEMBL1029548 0.79 KEAP1 (0.37) MAPTPOLBDRD3TSHR
SCHEMBL1027236 0.79 L3MBTL1 (0.47) LMNAMAPTPOLBMAPK14HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 US disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 LMNA 3028/4885MAPT 230/4885POLB 4635/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 LMNA 2551/4885MAPT 1767/4885POLB 1266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.